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Capsaicin 8% patch is cost-effective compared to pregabalin for patients who have 
failed one or more previous systemic treatments for PNP.
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Objectives: Multiple regimens are used in the treatment of severe haemophilia A 
in the Netherlands. Most patients receive clotting factors intravenously 2-3 times 
weekly to prevent bleedings: intermediate dose prophylaxis. Given the high utili-
zation of prophylaxis treatment, budget restraints might hinder the availability of 
prophylaxis for patients in the nearby future. Other treatment regimens are on-
demand (OD) treatment, administering clotting factors in case of bleedings, and 
prophylaxis treatment with a switch to OD at 18 years. This analysis estimates 
the cost-effectiveness of Dutch prophylaxis treatment for severe haemophilia A 
patients compared to other treatment regimens. MethOds: A Markov model is 
developed with the health stages ‘Alive’, ‘Severe joint damage’ and ‘Death’. Bleeding 
rates of individual patients are simulated over lifetime, including a probability of 
inhibitor development. A higher joint bleed rate is accompanied by increased joint 
damage, increasing the chance of joint surgery. Disease progression, within the 
Alive health state, is modeled with the Pettersson Score (PS). The PS indicates the 
radiographic arthropathy. Increased joint damage is associated with physical limita-
tions and decreased QoL. Because the chosen treatment regimen affects both the 
joint bleed rate and inhibitor development, it also affects the HRQoL. The analysis 
was performed from a societal perspective. Results: Prophylaxis treatment was 
associated with the greatest QoL. The cost-effectiveness acceptability curve shows 
a probability of 90% for prophylaxis treatment to be cost-effective at a threshold of 
€ 0, - compared to OD treatment. Compared to prophylaxis with a switch to OD at 
18 years, prophylaxis treatment has a 50% probability of being cost-effective at a 
€ 80.000, - threshold. The model outcome is sensitive for variations in bleeding rate, 
prophylaxis dosage, inhibitor development and utilities. cOnclusiOns: Based on 
our model, treatment of severe haemophilia A patients with lifetime prophylaxis 
is cost-effective compared to OD treatment.
PSY58
CoSt-EffECtivEnESS of thE lidoCAinE 5% mEdiCAtEd PlAStEr vErSuS 
PrEgAbAlin And AmitriPtYlinE for thE trEAtmEnt of PoSt-hErPEtiC 
nEurAlgiA in thE nEthErlAndS
Obradovic M.1, Vanden Baviere H.2, Liedgens H.3
1GfK Market Access, Nuremberg, Germany, 2Grünenthal, St Stevens Woluwe, Belgium, 
3Grünenthal GmbH, Aachen, Germany
Objectives: The objective of the analysis was to evaluate costs and outcomes 
of treating post-herpetic neuralgia (PHN), a chronic disease with severe burden 
for patients, in the Netherlands with lidocaine 5% medicated plaster compared to 
pregabalin and amitriptyline. MethOds: A Markov model was used to extrapolate 
outcomes beyond the time horizon of the available trial data and to allow for the 
fact that patients may discontinue treatment at any point during treatment. Costs 
and effects, expressed in terms of the quality-adjusted life-year (QALY) gained, 
were calculated for each treatment strategy over a period of 6 months. The study 
included direct costs related to PHN. Indirect costs were not included as most 
patients with PHN are older and retired. Transition probabilities were based on 
the comparative and long-term clinical trials. Utilites were identified through a 
literature review. Resource utilization was obtained from a two-step Delphi study 
with pain specialists, cost data were obtained from the official price tariffs/lists. 
Extensive sensitivity and scenario analyses were performed to explore robustness of 
the results. Results: In 6-month time horizon, treatment with the lidocaine plaster 
yielded 0.4283 QALYs. For pregabalin and amitriptyline the total effect was 0.3390 
QALYs. The mean costs per patient treated with lidocaine plaster (1.71 plasters/day) 
were 1,082 € . For pregabalin (488 mg/day) and amitriptyline (25 mg/day) the mean 
costs were 912 € and 346 € , respectively. Therefore, the lidocaine plaster compared 
to pregabalin and amitriptyline had an incremental cost-effectiveness ratio of 1,907 
€ /QALY and 8,246 € /QALY, respectively. Probability of the lidocaine plaster being 
cost-effective versus pregabalin and amitriptyline exceeded 90% when considering 
a threshold of 30,000 € per QALY gained. Extensive scenario and one-way sensitivity 
analyses confirmed robustness of the results. cOnclusiOns: The lidocaine 5% 
plaster is a highly cost-effective treatment for PHN in the Netherlands.
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Objectives: The main objective was to perform a pharmacoeconomic analysis 
to find out the cost effectiveness of diethylpropion (DEP) with diet and exercise. 
(DEP+DaE), compared against Diet and Exercise (DaE) in the treatment for obesity 
from the institutional point of view in Mexico. MethOds: Effectiveness data from 
a mexican clinical trial (Morin, 2007) was used to populate a decision tree model 
to estimate the cost-effectiveness of DEP+DaE and its comparator DaE. The target 
population were men and women over 18 years with BMI > 30 kg/m2. Principal 
outcome was the reduction of the Body Mass Index (BMI); benefit was expressed as 
the percentage of patients who reduced more than 10% of their initial weight. Only 
direct medical costs were used, such as medications and adverse events; these were 
obtained from the portal shop by IMSS and also from their unitary costs. To prove the 
Years Gained - LYG) and cost-utility analysis (Quality- Adjusted Life years – QALYs) 
were performed for a time horizon of 10 years according to a Markov economic 
model with four health states - “progression free survival (PFS) in first and second 
lines”, “progression” and “death” - and monthly cycles. Health states transition 
probabilities were obtained from two randomized controlled clinical trials: PRIMA 
(Salles G. et al 2010) and EORTC 20981 (van Oers M. et al 2010). Health state utili-
ties were obtained from literature (Pettengell R. et al 2008). Resource consumption 
was estimated by a Portuguese expert’s panel. Costs were calculated considering 
the Portuguese Health System perspective through official data (unit costs: € in 
2014). Costs and consequences were discounted at 5% per annum. Deterministic 
and probabilistic (Monte Carlo simulation) sensitivity analyses were performed for 
several assumptions namely time horizon, PFS supportive care and progression 
costs; adverse events costs; health states utilities values and costs and benefits 
annual discount. Results: For a 10 years’ time horizon, the cost per LYG and QALYs 
gained was € 10,630 and € 10,674 respectively. Sensitivity analyses confirmed the 
base case results for time horizons of 20 and 30 years, ranging between € 7,430 and 
€ 7,155 per QALY gained, respectively. Probabilistic sensitivity analysis confirmed 
the robustness of the model with a cost per QALY gained of € 10,657. The incre-
mental cost-effectiveness acceptability curve shows that rituximab maintenance 
therapy would be cost effective from a willingness to pay of € 12,000 per QALY 
gained. cOnclusiOns: According to the present model rituximab maintenance 
treatment of FL patients who respond to first line induction therapy compared with 
observation is a cost-effective strategy in Portugal.
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Objectives: The NHS newborn bloodspot screening programme currently screens 
all babies in England for five rare conditions. The objective of this study was to 
assess the cost-effectiveness of expanding the screening programme to include five 
new rare conditions all inborn errors of the metabolism; HCU, MSUD, GA1, IVA, and 
LCHADD. MethOds: A decision tree model was built to estimate the cost-effective-
ness of the expanded newborn screening programme. Estimates of the prevalence 
of the five conditions and the test characteristics of screening were taken from 
the literature. Survival and morbidity estimates for the screened and unscreened 
populations were estimated from published case series. Quality adjusted life years 
(QALYS) were estimated from the extended EQ-5D+ (C) which includes a cognitive 
dimension in order to capture the impact of neurological impairment and devel-
opmental delay which are known sequelae of the five conditions. Costs related to 
the marginal cost of the expanded screening programme, management costs of the 
conditions, and costs associated with the sequelae of the conditions were estimated 
from the pilot study of the expanded screening, case reports from the pilot, expert 
elicitation, published guidelines and estimates from the literature. Costs and QALYs 
were multiplied by survival and morbidity estimates to give lifetime estimates for 
the screened and unscreened populations. A probabilistic sensitivity analysis (PSA) 
was conducted. Results: The results from the deterministic analysis and PSA sug-
gests that screening for all five conditions is cost-saving with screening associated 
with lower total costs and higher total QALYs compared to no screening. The incre-
mental net benefit for all five conditions, at a threshold of £25,000 per QALY, was 
between £0.46 for IVA and £5.94 for GA1. cOnclusiOns: Screening for MSUD, HCU, 
IVA, GA1 and LCHADD are each estimated to be potentially cost saving and result 
in increased quality of life compared to no screening.
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CoSt-EffECtivEnESS of CAPSAiCin 8% PAtCh (QutEnzAtm) ComPArEd 
With PrEgAbAlin for thE trEAtmEnt of PAtiEntS With PEriPhErAl 
nEuroPAthiC PAin (PnP) in SCotlAnd
Patel S.1, Trueman D.2, Bentley A.2, Poole C.1, Chambers C.1
1Astellas Pharma Europe Ltd, Chertsey, UK, 2Abacus International, Bicester, UK
Objectives: PNP is a high-burden disease exacerbated by poor tolerability of con-
ventional oral therapies. Capsaicin 8% patch is a well-tolerated cutaneous treat-
ment for PNP in non-diabetic adults either alone or in combination with other 
therapies. We evaluated the cost-effectiveness of capsaicin 8% patch versus pre-
gabalin in patients with PNP from the perspective of NHS Scotland. MethOds: A 
decision tree model was developed considering patients with PNP who had neither 
achieved pain relief nor tolerated conventional first-/second-line treatments. After 
8 weeks’ treatment with capsaicin 8% patch or pregabalin, patients remained on 
therapy or discontinued due to intolerable adverse events. Patients continuing on 
therapy were classified as either responders (≥ 30% decrease in pain from baseline) 
or non-responders. Last-line therapy was given to non-responders and those who 
discontinued treatment. The base-case time horizon was 2 years. Effectiveness, 
discontinuations and quality of life utilities were estimated from a recent head-to-
head study (ELEVATE; NCT01713426). Other inputs were obtained from published 
sources or clinical expert opinion. All costs were based on GBP 2013/14. The results 
were presented as incremental cost-effectiveness ratios (ICERs), i. e. cost per quality-
adjusted life-year (QALY) gained. Model assumptions were tested with scenario 
analyses. Parameter uncertainty was tested using one-way and probabilistic sen-
sitivity analyses. Results: Compared with pregabalin, capsaicin 8% patch was 
dominant versus pregabalin (total cost difference, –£11 and total QALY gains, +0.049). 
Using a 1-year time horizon, the ICER increased to £1,242/QALY. The model was most 
sensitive to variations in time to capsaicin 8% patch retreatment (worse case ICER, 
£7,951/QALY). Capsaicin 8% patch was dominant in six/seven scenario analyses. 
At a willingness-to-pay threshold of £20,000/QALY gained, the probability of cost-
effectiveness for capsaicin 8% patch versus pregabalin was 97%. cOnclusiOns: 
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ment in chronic HCV infected patients with thrombocytopenia to enable INF-based 
treatment regimens from the Spanish Health System perspective. MethOds: A 
two-phase individual-level model was developed to evaluate the cost-effectiveness 
of eltrombopag treatment in thrombocytopenic HCV-patients over a lifetime hori-
zon. Individual-level models are more flexible and provide more accurate estima-
tions than Markov approaches. One million patients were simulated using data from 
trials ENABLE 1 and 2 and local studies. In the first phase, a discrete event simulation 
was used to recreate patient events during INF-treatment. When eltrombopag was 
considered, patients underwent an initial pre-INF treatment with eltrombopag. 
Those that failed to reach INF-label platelet count did not receive INF-based regi-
mens. In the second phase, a microsimulation was used to emulate each patient 
from treatment discontinuation to death. Health states included fibrosis (F0, F1/2, 
F3, F4), liver decompensation, hepatocelullar carcinoma, liver transplant and death. 
Transition probabilities for each 1-month cycle, utilities and direct health care costs 
(€ 2014) were obtained from literature and national databases. A 3% annual discount 
was applied to costs and health outcomes. Sensitivity analysis with 0% and 5% 
discount rates were performed. Results: Eltrombopag was associated with an 
average increment of 0.58 quality-adjusted life years (QALY) and an additional cost 
of € 17,084.47/patient. The average incremental cost effectiveness ratio (ICER) was 
29,808.26 € /QALY. Considering a € 30,000 threshold, eltrombopag was cost-effective 
in 59.12% of cases. This proportion remained similar with 5% (56.7%) and 0% (63.25%) 
discount rates. cOnclusiOns: With the premises considered in this study, eltrom-
bopag in HCV patients could be considered cost-effective from the Spanish Health 
System perspective.
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Objectives: To assess the cost-effectiveness of romiplostim in the treatment of 
Adult Immune Thrombocytopenia (ITP) in Portugal, versus eltrombopag and current 
medical standard of care (SoC). MethOds: A lifetime treatment-sequence cost-utility 
Markov model with an embedded decision tree was developed from the Portuguese 
Healthcare Payer perspective to compare romiplostim with eltrombopag and SoC in 
splenectomized patients, non-splenectomized patients and a combined population. 
Treatment sequences and health care utilization were validated by a Portuguese 
expert in ITP. Outcomes included incremental cost-utility ratio (ICUR). Costs (€ , 2014) 
included drug acquisition costs and costs associated with monitoring patients and 
managing complications. Results: In the combined population, romiplostim versus 
eltrombopag had incremental costs (IC) of 13.848€ and a quality-adjusted life-years 
(QALY) gain of 0,566, yielding an ICUR of 24.451€ . Compared with SoC, romiplostim 
had IC of 18.622€ and a QALY gain of 0,938, yielding an ICUR of 19.848€ . In splenecto-
mized patients, the most prevalent sub-population in Portugal (65% of adult chronic 
ITP patients), romiplostim had an ICUR of 6.304€ versus eltrombopag and an ICUR 
of 3.179€ versus SoC. One-way sensitivity analysis showed that the model was most 
sensitive to variations in the drug doses/ percentage of utilization and costs (romi-
plostim, eltrombopag and intravenous immunoglobulin) and to the utility of patients 
responding to ITP treatments. In the combined population the probabilistic sensitiv-
ity analysis showed that romiplostim is likely to be cost-effective in 66% and 84% of 
samples versus eltrombopag and versus SoC at a willingness-to-pay threshold of 
30.000€ /QALY, respectively. cOnclusiOns: Use of romiplostim in the ITP treatment 
pathway, compared with eltrombopag or SoC, is likely to be cost-effective in Portugal.
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Objectives: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune inflam-
matory disease, associated with significant health and socioeconomic burden. 
Current treatment of SLE involves glucocorticoids, antimalarials, non-steroid anti-
inflammatory drugs, and immunosuppressive agents. Belimumab, a human IgG 
monoclonal antibody specific for soluble human B lymphocyte stimulator protein, 
is a novel pharmaceutical treatment approved as an add-on therapy in adult SLE 
patients with highly active disease (autoantibody-positive and low complement 
levels) despite treatment. The study objective was to estimate the incremental 
cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) of adding 
belimumab to the Standard-of-Care (SoC) treatment of SLE patients with high dis-
ease activity in the Greek health care setting. MethOds: The analysis is based on 
the local adaptation of a micro-simulation model. The model follows individual 
patients over a lifelong period. Data on short-term outcomes were sourced from two 
randomized controlled trials (BLISS 72/7614). Long-term outcomes were estimated 
via natural history models developed on the basis of data from the John Hopkins 
cohort of SLE patients. Direct costs consisted of short-term disease activity related 
costs, organ damage costs, SoC treatment and belimumab administration costs. 
Short-term costs and costs of treatment were calculated on the basis of resource 
utilisation elicited from a panel of experts and using list prices (2013 prices). Organ 
damage costs were identified through a literature review. Results were discounted at 
3.5% for both costs and effects. The study was performed from the perspective of the 
health care payer. Results: Treatment with belimumab+SoC resulted in 0.81 added 
life years and 0.377 QALYs (Quality-Adjusted Life Years). This resulted in 18,350€ / 
LYG (Life-Year-Gained) and 27,254€ /QALY. cOnclusiOns: Cost-effectiveness and 
cost-utility ratios of belimumab compared to SoC treatment are below internation-
ally applied thresholds. Belimumab can be considered as an add-on therapy to SoC 
for the treatment of SLE patients with highly active disease in Greece.
strength of the analysis, deterministic and probabilistic sensitivity tests were per-
formed; all the quantities are expresed in Mexican pesos (MXP) at 2013. Results: 
Both groups lose weight and reduce their BMI. However, these changes were earlier 
and more pronounced in the (DEP+DaE) group. DeP+DaE presented a significant 
higher percentage of patients reducing 10% of their intial weight (37% vs 17%, 
p-value< .05). Incremental cost was $1,455.09 MXP and incremental effectiveness 
was 20% in reducing the initial weight. The incremental cost-effectiveness ratio of 
(DEP+DaE) relative to DaE was calculated to be $7,374.07 MXP per additional percent-
age of reduction suggesting that DEP+DaE is cost-effective compared with DaE as 
a treatment for obesity in Mexico. cOnclusiOns: The combination of DEP+DaE 
provides a cost effective improvement to the treatment of patients with a risk profile 
for obesity in Mexico.
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Objectives: To perform a complete economic evaluation type using oxycodone 
(Endocodil XR ®) versus morphine, buprenorphine (transdermal patches) and fen-
tanyl (transdermal patches) on moderate to severe pain secondary to cancer type 
in Mexico, from the point of view of public health. MethOds: A cost-effectiveness 
analysis was made, a decision tree model was developed to simulate the costs and 
benefits of health outcomes of each opioid analgesic, the probabilities were obtained 
through a systematic review of the literature. The model has 13 cycles of 28 days 
under a time horizon of 364 days, the main measure of effectiveness was deter-
mined as days without severe adverse events and pain controlled, only measured 
direct medical costs and the ratio was obtained incremental cost-effectiveness, 
further a deterministic sensitivity analysis, probabilistic sensitivity analysis and 
budget impact was performed. Results: The results demonstrate that oxycodone 
(Endocodil XR ®) is a dominant option respect to Buprenorphine (PT), fentanyl (PT), 
the results showed 309 days without severe adverse events and controlled pain 
compared to 219 and 255 respectively Oxycodone had a cost of $ 57,702.34 under $ 
58,254.43 and 129,906.49 costing of their comparators respectively, compared to mor-
phine oxycodone is more effective but more expensive, it had an ICER of $ 202.05, 
sensitivity analysis and budget impact showed that oxycodone remains an option 
cost-saving. cOnclusiOns: The results demonstrate that oxycodone (Endocodil XR 
®) is a cost-effective option for the treatment of patients with pain of moderate to 
severe secondary to cancer in Mexico, it is an option that effectively combines price 
and fails to meet the necessary standards for palliative care and pain management.
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PoSAConAzolE, fluConAzolE And itrAConAzolE With thE PurPoSE 
of PrimArY PrEvEntion of invASivE fungAl infECtion in PAtiEntS 
With nEutroPEniA during ChEmothErAPY for ACutE mYElogEnouS 
lEukEmiA or mYElodYSPlAStiC SYndromE
Krysanov I.1, Krysanova V.2
1Postgraduate Medical Institute, Moscow National University of Food Production, Moscow, Russia, 
2I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To perform ñomparative pharmacoeconomic analysis of alternative 
schemes for prevention of invasive mycosis with fluconazole, itraconazole and 
posaconazole in patients with neutropenia, after chemotherapy for acute myelog-
enous leukemia or myelodysplastic syndrome. MethOds: Were reviewed research 
on the clinical effectiveness and safety of use of Posaconazole. Assess of the qual-
ity of research and level of evidence obtained in these results was performed. The 
model is constructed on the basis of the results of a multicenter randomized trial 
Cornely O. A. et al., 2007. The model calculated the differences in direct medical 
costs for the use of drugs, as well as the cost of medical treatment cases inva-
sive mycosis the ineffectiveness of primary prevention. The duration of preventive 
treatment, the probability of various outcomes correspond to the data of speci-
fied clinical study. Results: Analysis of the evidence has shown that on patients 
with neutropenia antifungal prophylaxis with posaconazole is more effective than 
fluconazole/itraconazole, and significantly reduces the risk of developing invasive 
mycosis, and associated mortality. Total costs for the use of posaconazole was 13169 
USD, that by 24.6 % higher than the use of fluconazole (total costs 9932 USD) and 
24.3 % higher than itraconazole (total costs 9965 USD). Also use of posaconazole has 
increased the total number of LYG by 6%. The ICER was $ 21339 USD and 21117 USD 
compared to fluconazole and itraconazole, and lower than the estimated threshold 
of willingness to pay in the Russian Federation equal 38390 USD. One-way sensi-
tivity analysis showed that in case of changes in the cost of posaconazole from 
75% to 125 %, the ICER for a one LYG do not exceed the threshold of willingness 
to pay. cOnclusiOns: Use of Posaconazole for prevention of invasive mycosis in 
patients with neutropenia is economically justified.
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Objectives: Thrombocytopenia limits the use of interferon (INF) based regimens 
in chronic hepatitis C virus (HCV) patients. Eltrombopag, a thrombopoietin-receptor 
agonist, effectively elevates platelet count allowing optimal INF-treatment. The 
objective of the present study was to assess the cost-effectiveness as support treat-
